Labcorp and the Children’s Hospital of Philadelphia are partnering to accelerate pediatric diagnostic innovation and national access, signaling new growth opportunities for clinical laboratories in high-complexity, specialty testing markets.
Labcorp and the Children’s Hospital of Philadelphia (CHOP) have announced a strategic collaboration aimed at accelerating the development and commercialization of specialized pediatric diagnostics.
This effort could potentially reshape how clinical laboratories access and deliver advanced testing for younger patient populations.
For clinical laboratory professionals, the partnership signals a growing emphasis on
scaling niche, high-complexity diagnostics through national infrastructure. By combining CHOP’s pediatric research and clinical expertise with Labcorp’s commercialization capabilities and broad testing network, the organizations plan to build a joint innovation pipeline designed to move new assays from discovery to nationwide availability more efficiently.
Labcorp–CHOP Collaboration Targets Pediatric Testing Gap
This model addresses a longstanding gap in the diagnostics market. Pediatric-specific tests, which account for developmental and physiological differences, have historically lagged behind adult-focused diagnostics. The collaboration targets key growth areas including oncology, metabolic disease, autoimmune disorders, and rare diseases—segments that increasingly require advanced molecular and genetic testing capabilities.
“Our shared aim to improve children’s health makes this collaboration so powerful,” Stephen R. Master, division chief and director of metabolic and advanced diagnostics at CHOP, said in a news release. “By pairing CHOP’s pediatric leadership with Labcorp’s nationwide reach, we seek to deliver important new and specialized tests to children and their families more efficiently and at greater scale.” (Photo credit: CHOP)
From a business perspective, the agreement reflects a broader industry trend toward partnerships that bridge academic innovation with commercial scale. For clinical laboratories, it underscores the opportunity and competitive pressure to expand pediatric test menus, invest in specialized capabilities, and align with research institutions to accelerate time to market.
The agreement also illustrates Labcorp’s continuing effort to expand its presence in the US diagnostics market. Labcorp and chief competitor Quest Diagnostics have been on buying sprees in recent years to grab laboratory outreach businesses from health systems. The CHOP partnership represents a different business avenue for Labcorp to head into.
As demand grows for precision diagnostics in younger populations, collaborations like this may define the next phase of growth in the clinical lab industry, particularly in high-value, specialty testing segments.
—Janette Wider
